Dec. 18 (Bloomberg) -- Roche Holding anti-tumor drug Avastin fails to win backing of U.K. health-cost regulator as treatment for advanced ovarian cancer in a draft decision released today.
* National Institute for Health and Clinical Excellence
recommends against using drug at dosage for which it’s
currently licensed, the agency says in e-mailed statement * Roche will continue to work with NICE to secure positive
recommendation for Avastin, spokeswoman Silvia Dobry says in
Story: NSN MF6PHR6JIJVI <GO> For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>